ATOPIC DERMATITIS: NEW ASPECTS OF TREATMENT
https://doi.org/10.15690/vsp.v12i5.802
Abstract
Atopic dermatitis is a chronic inflammatory cutaneous disease, which demands a prolonged treatment. A modern views on the main approaches to treatment of atopic dermatitis in children and adults are analyzed in this article. The treatment is based on the permanent use of emollients in order to achieve an anti-inflammatory effect — topical calcineurin inhibitors (tacrolimus and pimecrolimus), and short courses (5 days) of topical corticosteroids during relapses. For the 10-year period of topical calcineurin inhibitors usage in treatment of atopic dermatitis a great amount of experimental and clinical data have been accumulated. Two the most important changes and additions in the treatment of atopic dermatitis in recent times were related to a new hypothesis of proactive therapy with the use of topical tacrolimus and closing of «black box» warnings, associated to malignization risk due to the long-term usage of topical calcineurin inhibitors. Since atopic dermatitis is characterized by relapsing course, nowadays topical tacrolimus should be considered the most appropriate treatment approach, both in adults and children. The results of investigations confirmed more than 6-times decrease in relapse rate, as well as the significant improvement of quality of life, when the above-mentioned treatment scheme is used, both in children and adults.
Key words: children, atopic dermatitis, emollients, treatment, tacrolimus.
About the Author
D. Sh. Macharadze
People’s Friendship University of Russia, Moscow
Russian Federation
Macharadze Dali Shotaevna, Doctor of Medical Sciences, Professor of the Department of Allergy and Clinical Immunology
Russian Federation
Macharadze Dali Shotaevna, Doctor of Medical Sciences, Professor of the Department of Allergy and Clinical Immunology
References
1. Saavedra J., Boguniewicz M., Chamlin S., Lake A., Nedorost S., Czerkies L., Patel V., Botteman M., Horodniceanu E. Patterns of clinical management of atopic dermatitis in infants and toddlers: A survey of three physician specialities in the United States. J. Pediatr. 2013; 14: 168–171.
2. Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J. Am. Acad. Dermatol. 2008; 9: 68–73.
3. Leung D., Nicklas R., Li J., Bernstein I., Blessing-Moore J., Boguniewicz M., Chapman J., Khan D., Lang D., Lee R., Portnoy J., Schuller D., Spector S., Tilles S. Disease management of atopic derma titis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann. Allergy Asthma Immunol. 2004; 9 (Suppl. 2): 1–21.
4. Macharadze D.Sh. Atopicheskiy Dermatit: Sovremennye Metody Diagnostiki i Terapii. Uchebno-Metodicheskoe Posobie [Atopic Dermatitis: Modern Methods of Diagnosis and Therapy. A Teaching Manual]. Moscow, RPK “Liniya-Print” Publ., 2011. 75 p.
5. Suarez-Farinas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong K., Krueger J., Guttman-Yassky E. Intrinsic atopic dermatitis shows similar Th2 and higher Th17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 2013; 132: 361–370.
6. Segal A., Ellis А., Kim H. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin. Immunol. 2013; 9 (1): 24–29.
7. Fleischer A., Boguniewicz M. An approach to pruritus in atopic dermatitis: A critical systematic review of the tacrolimus ointment literature. J. Drugs Dermatol. 2010; 9: 488–498.
8. Meingassner J., Aschauer H., Stuetz A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroidpretreated skin. Exp. Dermatol. 2005; 14: 752–757.
9. McCollum A., Paik A., Eichenfield L. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr. Dermatol. 2010; 9: 425–436.
10. Svensson A., Chambers C., Ganemo A., Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr. Med. Res. Opin. 2011; 12: 1385–1406.
11. Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U. K. National Health Service) perspective. Brit. J. Dermatol. 2011; 164: 387–395.
12. Tennis P., Gelfand J., Rothman K. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Brit. J. Dermatol. 2011; 165: 465–473.
13. Miyagaki T., Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J. Dermatol. Sci. 2011; 64: 1–6.
14. Siegfried E., Jaworski J., Hebert A. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am. J. Clin. Dermatol. 2013; 14: 163–178.
15. Mandelin J., Remitz A., Reitamo S. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. Arch. Dermatol. 2010; 146: 10.
Review
For citations:
Macharadze D.Sh. ATOPIC DERMATITIS: NEW ASPECTS OF TREATMENT. Current Pediatrics. 2013;12(5):80-85. (In Russ.) https://doi.org/10.15690/vsp.v12i5.802
Views:
2150
Email this article 
